Since Ubc13 is a unique E2 that catalyzes formation of K63-linked polyubiquitin chains on various substrates, Ubc13 inhibitor is expected to be a novel candidate for the treatment of cancer and inflammatory diseases31. The gene discussed is UBE2N; the disease is cancer.